RxDoctor Payments Data

Heidi Hassler, PA

Physician Assistant · Vermillion, SDNPI 1548874688

Payments from drug & device makers

$1,242in general payments, 2019–2025

Across 60 payments — averaging $20.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$250
  • Mallinckrodt Hospital Products Inc.$138
  • AstraZeneca$125
  • Otsuka America Pharmaceutical, Inc.$102
  • Kyowa Kirin, Inc.$76
  • Nestle Healthcare Nutrition Inc.$73
  • plus $479 from 15 others

What the payments were for

  • Food & beverage$1,18095%
  • Education$625%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,242 in reported general payments places this provider in the 80th percentile of 548 physician assistant providers in South Dakota.

See all physician assistant providers in South Dakota

Medicare billing

Part B allowed, 2024
$174,972
Medicare patients
599
Services billed
8,943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol108$63,925
JanuviaSitagliptin Phosphate45$20,916
JardianceEmpagliflozin24$14,786
OzempicSemaglutide14$11,964
KerendiaFinerenone14$9,004
Bumetanide278$6,187
Cinacalcet Hcl73$5,987
Potassium Chloride371$4,681
MyrbetriqMirabegron13$3,871
Midodrine Hcl52$3,067
Allopurinol631$3,012
Calcitriol324$2,574
Hydralazine Hcl193$1,568
Furosemide465$1,212
Febuxostat28$1,203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$125$63,925108 claims
Boehringer IngelheimJardiance$42$14,78624 claims
Novo NordiskOzempic$16$11,96414 claims
BayerKerendia$42$9,00414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 548 physician assistant providers in South Dakota.

Other physician assistant in Vermillion

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →